• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Lifeward to Present at Sidoti Virtual Investor Conference on May 21

    5/19/25 6:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care
    Get the next $LFWD alert in real time by email

    MARLBOROUGH, Mass., and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward, Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Larry Jasinski, Chief Executive Officer, will make a corporate presentation and host one-on-one meetings with investors at the Sidoti May Virtual Investor Conference, taking place on May 21-22, 2025. Joining him will be Mike Lawless, Chief Financial Officer.

    The presentation will begin at 10:00 AM EDT on May 21, 2025 and can be accessed live here: https://sidoti.zoom.us/webinar/register/WN_5U4M2xfKTV2ItMDBl5E3-w. Lifeward will also host virtual one-on-ones with investors on Wednesday and Thursday, May 21-22, 2025. To register for the presentation or one-on-ones, visit www.sidoti.com/events. Registration is free and interested investors do not need to be Sidoti clients.

    About Lifeward

    Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity system, the MyoCycle FES System, and the ReStore Exo-Suit.

    Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward mission and product portfolio, please visit GoLifeward.com.

    Lifeward®, ReWalk®, ReStore®, and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.

    Lifeward Media Relations:

    Kathleen O'Donnell

    Vice President, Marketing & New Business Development

    Lifeward Ltd.

    E: [email protected] 



    Lifeward Investor Contact:

    Mike Lawless

    Chief Financial Officer

    Lifeward Ltd.

    E: [email protected] 



    Primary Logo

    Get the next $LFWD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LFWD

    DatePrice TargetRatingAnalyst
    2/10/2025$10.00Buy
    Laidlaw
    More analyst ratings

    $LFWD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Turk Joseph E Jr bought $10,140 worth of Ordinary Shares (6,000 units at $1.69), increasing direct ownership by 48% to 18,516 units (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      12/17/24 8:55:09 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Director Swinford Michael bought $43,858 worth of Ordinary Shares (21,622 units at $2.03), increasing direct ownership by 50% to 65,040 units (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      11/27/24 8:03:53 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Director Swinford Michael bought $30,899 worth of Ordinary Shares (16,907 units at $1.83), increasing direct ownership by 64% to 43,418 units (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      11/26/24 7:07:36 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lifeward Names Mark Grant as New CEO

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Mark Grant has been appointed as the Company's new President and Chief Executive Officer, effective June 2, 2025. Larry Jasinski, Lifeward's outgoing CEO, will serve as Co-CEO and, as previously announced, will serve in an advisory capacity until the end of June to assist with the transition, and thereafter on an as-needed basis through the end of 2025. "Mark brings 30 years of combined experience in commercia

      5/19/25 8:30:00 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward to Present at Sidoti Virtual Investor Conference on May 21

      MARLBOROUGH, Mass., and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward, Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Larry Jasinski, Chief Executive Officer, will make a corporate presentation and host one-on-one meetings with investors at the Sidoti May Virtual Investor Conference, taking place on May 21-22, 2025. Joining him will be Mike Lawless, Chief Financial Officer. The presentation will begin at 10:00 AM EDT on May 21, 2025 and can be accessed live here: https://sidoti.zoom.us/webinar/register/WN_5U4M2xfKTV2ItMDBl

      5/19/25 6:00:00 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward Ltd. Reports First Quarter 2025 Financial Results

      U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved operating expense trend Second consecutive quarter of AlterG revenue growth over 15% reflecting continued sales momentum MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months ended March 31, 2025. Recent Highlights and A

      5/15/25 8:00:33 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Lind Global Fund Ii Lp sold $1,655,009 worth of Ordinary Shares (573,110 units at $2.89) (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      1/8/25 5:20:52 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Director Richner Randel sold $7,214 worth of Ordinary Shares (4,285 units at $1.68) (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      12/17/24 4:08:29 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Director Turk Joseph E Jr bought $10,140 worth of Ordinary Shares (6,000 units at $1.69), increasing direct ownership by 48% to 18,516 units (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      12/17/24 8:55:09 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Financials

    Live finance-specific insights

    See more
    • Lifeward Ltd. Reports First Quarter 2025 Financial Results

      U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved operating expense trend Second consecutive quarter of AlterG revenue growth over 15% reflecting continued sales momentum MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months ended March 31, 2025. Recent Highlights and A

      5/15/25 8:00:33 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward to Report First Quarter 2025 Financial Results on May 15, 2025

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a  global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its first quarter 2025 financial results before the markets open on Thursday, May 15, 2025. Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-316-0561International (

      5/7/25 4:30:25 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward to Report Fourth Quarter and Fiscal Year-End 2024 Financial Results on March 7, 2025

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a  global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its fourth quarter and fiscal year-end financial results before the markets open on Friday, March 7, 2025. Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-3

      2/28/25 8:00:16 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    SEC Filings

    See more
    • Lifeward Ltd. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Lifeward Ltd. (0001607962) (Filer)

      5/19/25 8:40:33 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • SEC Form S-3 filed by Lifeward Ltd.

      S-3 - Lifeward Ltd. (0001607962) (Filer)

      5/15/25 4:06:12 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by Lifeward Ltd.

      10-Q - Lifeward Ltd. (0001607962) (Filer)

      5/15/25 9:00:43 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Laidlaw initiated coverage on Lifeward with a new price target

      Laidlaw initiated coverage of Lifeward with a rating of Buy and set a new price target of $10.00

      2/10/25 7:00:44 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Leadership Updates

    Live Leadership Updates

    See more
    • Lifeward Names Mark Grant as New CEO

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Mark Grant has been appointed as the Company's new President and Chief Executive Officer, effective June 2, 2025. Larry Jasinski, Lifeward's outgoing CEO, will serve as Co-CEO and, as previously announced, will serve in an advisory capacity until the end of June to assist with the transition, and thereafter on an as-needed basis through the end of 2025. "Mark brings 30 years of combined experience in commercia

      5/19/25 8:30:00 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward Announces Appointment of Robert J. Marshall to Its Board of Directors

      MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions in physical rehabilitation and recovery, announced the Board of Directors has approved the appointment of Robert J. Marshall Jr. as a new director effective November 2, 2024. As part of his duties as a director, Mr. Marshall will serve as Chairman of the Audit Committee. Mr. Marshall has had a long and accomplished finance career in the medical device industry. Currently, Mr. Marshall serves as the Chief Financial Officer and Treasurer of Lantheus Holdings, Inc., a publicly traded radiopharmaceut

      11/7/24 4:05:14 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward Announces Appointment of Dr. Keith E. Tansey as Consulting Director of Clinical Research

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™) (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that Dr. Keith E. Tansey, MD, PhD, will be joining its Medical Affairs team as a consultant in the role of Director, Clinical Research. Dr. Tansey's responsibilities will include the development and stewardship of Lifeward's clinical research program, the advancement of key opinion leader opportunities, and iden

      9/10/24 8:30:00 AM ET
      $LFWD
      Industrial Specialties
      Health Care